Illumina (ILMN)
(Delayed Data from NSDQ)
$137.32 USD
-1.36 (-0.98%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $136.39 -0.93 (-0.68%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Illumina (ILMN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$152.74 | $258.00 | $85.00 | 10.14% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Illumina comes to $152.74. The forecasts range from a low of $85.00 to a high of $258.00. The average price target represents an increase of 10.14% from the last closing price of $138.68.
Analyst Price Targets (19)
Broker Rating
Illumina currently has an average brokerage recommendation (ABR) of 2.26 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 2.26 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 42.11% and 5.26% of all recommendations. A month ago, Strong Buy made up 42.11%, while Buy represented 5.26%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.26 | 2.26 | 2.26 | 2.26 | 2.26 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
2/14/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
2/8/2024 | Robert W. Baird & Co. | Catherine W Schulte | Hold | Hold |
12/19/2023 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
11/10/2023 | Canaccord Genuity | Kyle Mikson | Strong Buy | Hold |
11/10/2023 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
8/10/2023 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.26 |
ABR (Last week) | 2.26 |
# of Recs in ABR | 19 |
Average Target Price | $152.74 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 252 |
Current Quarter EPS Est: | 0.03 |